Abstract: The present invention is concerned with a modified release pharmaceutical composition comprising an effective amount of at least one antipsychotic agent so that the antipsychotic agent(s) are released in such a manner to better accord with physiological and chronotherapeutic requirements of patients.

Abstract: Disclosed herein is an oral dosage formulation suitable for treating a neurodegenerative disorder. The oral dosage formulation contains both sustained-release and immediate-release drugs. The sustained-release drug in the oral dosage formulation is memantine, and the immediate-release drug in the oral dosage formulation is donepezil and/or memantine, and the formulation is characterized in having a pH-independent dissolution profile of memantine at a pH range from about 1.0 to about 7.0.

Abstract: The present invention is concerned with a modified release pharmaceutical composition comprising an effective amount of at least one antipsychotic agent so that the antipsychotic agent(s) are released in such a manner to better accord with physiological and chronotherapeutic requirements of patients.

Abstract: Disclosed herein is an oral dosage formulation suitable for treating a neurodegenerative disorder. The oral dosage formulation contains both sustained-release and immediate-release drugs. The sustained-release drug in the oral dosage formulation is memantine, and the immediate-release drug in the oral dosage formulation is donepezil and/or memantine, and the formulation is characterized in having a pH-independent dissolution profile of memantine at a pH range from about 1.0 to about 7.0.

Abstract: Disclosed is a double-layered tablet containing zaleplon. The tablet includes an instant release layer and a delayed release layer. The instant release layer contains zaleplon, lactose, maltose, microcrystalline cellulose, sodium lauryl sulfate, and at least one excipient. The delayed release layer contains zaleplon, maltose, microcrystalline cellulose, a polymer, and at least one excipient. A dissolution curve is obtained for the double-layered zaleplon-contained tablet by using a 0.1N hydrochloric acid buffer and pH 6.8 phosphoric acid buffer contained in stirring devices having rotatable blades with stirring speeds of 50-200 RPM, and the release of zaleplon is controlled in such a way to follow the dissolution curve, so as to provide the advantages of improving sleep quality, enhancing safety of medicine use, being convenient to use, and offering flexible dosing.

Abstract: The present invention is directed to compositions and methods for the transdermal delivery of a pharmaceutically active compound. In some embodiments, the addition of inert pharmaceutical ingredients in place of a portion of adhesive in a transdermal patch formulation increases the rate of skin permeation of a pharmaceutical compound.